• DOI:10.1038/s41572-020-0210-0
• Corpus ID: 221861310

Epidermolysis bullosa

@article{Bardhan2020EpidermolysisB,
  title={Epidermolysis bullosa},
  author={Ajoy Bardhan and Leena Bruckner-Tuderman and Iain L C Chapple and J‐D. Fine and Natasha Harper and Cristina Has and Thomas M. Magin and M. Peter Marinkovich and John F Marshall and John A. McGrath and Jemima E. Mellerio and Rex Polson and Adrian H M Heagerty},
  journal={Nature Reviews Disease Primers},
  year={2020},
  volume={6},
  pages={1-27}
}

• A. Bardhan, L. Bruckner-Tuderman, +10 authors A. Heagerty
• Published 24 September 2020
• Medicine, Biology
• Nature Reviews Disease Primers

Epidermolysis bullosa (EB) is an inherited, heterogeneous group of rare genetic dermatoses characterized by mucocutaneous fragility and blister formation, inducible by often minimal trauma. A broad phenotypic spectrum has been described, with potentially severe extracutaneous manifestations, morbidity and mortality. Over 30 subtypes are recognized, grouped into four major categories, based predominantly on the plane of cleavage within the skin and reflecting the underlying molecular abnormality: EB simplex, junctional EB, dystrophic EB and Kindler EB. The study of EB has led to seminal advances in our understanding of cutaneous biology. To date, pathogenetic mutations in 16 distinct genes have been implicated in EB, encoding proteins influencing cellular integrity and adhesion. Precise diagnosis is reliant on correlating clinical, electron microscopic and immunohistological features with mutational analyses. In the absence of curative treatment, multidisciplinary care is targeted towards minimizing the risk of blister formation, wound care, symptom relief and specific complications, the most feared of which — and also the leading cause of mortality — is squamous cell carcinoma. Preclinical advances in cell-based, protein replacement and gene therapies are paving the way for clinical successes with gene correction, raising hopes amongst patients and clinicians worldwide. Epidermolysis bullosa (EB) is a heterogeneous group of rare inherited genetic diseases characterized by mucocutaneous fragility and blister formation. This Primer describes the broad phenotypic spectrum of EB, including its potentially severe extracutaneous manifestations, as well as outlining the current mechanistic understanding and approaches to managing patients.